Aspirin to Target Arterial Events in Chronic Kidney Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 4633 participants.
Also called NCT03796156
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 4,633 participants
- Sponsor
- Registry
-
NCT03796156
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT03796156. Randomized; single masking; primary purpose prevention. Start 2019-02-25 (actual); primary completion 2024-09-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Aspirin to Target Arterial Events in Chronic Kidney Disease
- Acronym
- ATTACK
- Condition
- Chronic Kidney Diseases
- Condition
- Cardiovascular Diseases
- Condition
- Bleeding
- Intervention (Drug)
- Aspirin
- Lead sponsor
- University of Southampton
- Collaborator
- University of Nottingham
- Collaborator
- University of Warwick
- Collaborator
- Nottingham University Hospitals NHS Trust
- Collaborator
- East Kent Hospitals University NHS Foundation Trust
- Collaborator
- University of Durham
- Collaborator
- Epsom and St Helier University Hospitals NHS Trust
Record details
- Record id
cardio:ct-nct03796156- Content hash
1e97bd8017ba9da80ac4a1783c465939fb2584f2958cbf729579f7157f3170fa